Home Superbug News - CoronaVirus Watch List

Superbug News - CoronaVirus Watch List

The Superbug Stock Review. Deadly Antibiotic-Resistant Bacteria like ‘Candida Auris’ and Deadly and Virulent Viruses Like ‘CoronaVirus’ or ‘HIV’ which killed 32 million. If Wall Street Funded Biotechs Are Trying to Kill What Wants to Kill Us, We’ll Follow It.

GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.

(Presentation text bolding for emphasis by Editors of the Biotech Stock Review, not the company.

Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.

Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for...

Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.

Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List...

GeoVax (GOVX) Research Reports Archive

Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research....

Adding Geovax (GOVX) to 2024 Biotech Watch List.

GEOVAX (GOVX) $0.32 We added this to the Watch List earlier in the...

Bridging the Immunity Gap: An In-Depth Conversation with GeoVax’s (GOVX) CEO, David Dodd

In an era of rapid scientific development, the pharmaceutical industry constantly evolves to meet new challenges and seize emerging opportunities. GeoVax, a...

YIKES! New Form of Antimicrobial Resistance Discovered – One of the World’s Greatest Health...

A new mechanism has been discovered that enables bacteria to take up nutrients from their human host and bypass antibiotic treatment. This...

Provention Biosciences (PRVB) Enters the Danger Zone.

Chart Looks Beautiful - But Nervous is why, we use soft and dry. LIVE QUOTE We'll...

VERU (VERU) $6.66, Goes Poof.

Veru Provides Update on FDA Advisory Committee Meeting Market Cap Plunges from...
Dr John Fahy UCSF

Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...

Latest article

Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!

When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...

GeoVax to Provide Corporate Update on Tuesday May 14, 2024.

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...

NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...